Pre-made Odulimomab benchmark antibody (Fab Fusion, anti-ITGAL therapeutic antibody, Anti-CD11A/LFA-1/LFA1A Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Odulimomab benchmark antibody (Fab Fusion, anti-ITGAL therapeutic antibody, Anti-CD11A/LFA-1/LFA1A Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Odulimomab is an investigational drug for the prevention of transplant rejection[1][2] and for the treatment of various immunological diseases.[3][4]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-931-1mg	1mg	3090
GMP-Bios-INN-931-10mg	10mg	Inquiry
GMP-Bios-INN-931-100mg	100mg	Inquiry
GMP-Bios-INN-931-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Odulimomab Biosimilar, Fab Fusion, Anti-Itgal Antibody: Anti-CD11A/LFA-1/LFA1A therapeutic antibody
INN Name	Odulimomab
Target	ITGAL
Format	Fab Fusion
Derivation	Mus musculus
Species Reactivity	human
CH1 Isotype	F(ab')2 - G1 - nd
VD LC	F(ab')2 - G1 - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Pasteur M (Lyon France)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0